AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (AARD) to Filing of Securities Class Action
Hagens Berman issued a shareholder-solicitation notice regarding Aardvark Therapeutics (AARD); no new disclosure from the company itself. The lawsuit alleges Aardvark misled investors about the safety of its lead asset ARD-101 and failed to disclose cardiac observations that led to an FDA clinical hold.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.